Skip to content

Superficial Basal Cell Carcinoma

Superficial basal cell carcinoma (sBCC) is a subtype of basal cell skin cancer that grows mainly near the surface. A flat scaly patch is not enough for diagnosis because eczema and other cancers can look similar.

Aldara

Imiquimod

5%

Designed to target viral or abnormal cell lesions and to alleviate site-specific skin conditions.

From$10.13/ sachetView

Key takeaways

  • sBCC often appears as a slowly enlarging pink or red scaly patch, sometimes with bleeding or a fine raised edge.
  • Examination and often biopsy establish subtype, depth and borders before treatment is selected.
  • Surgery usually offers margin assessment; topical treatment has selected roles for low-risk lesions and requires follow-up for recurrence.

Catalogue matches do not confirm sBCC or show that a topical immune treatment is appropriate.

What makes a lesion low or high risk?

Size, location, border definition, previous treatment, immune status and pathology affect recurrence risk. Lesions near eyes, nose, ears or lips and recurrent or aggressive tumours often need procedural management.

When is topical treatment considered?

Imiquimod may be considered for selected confirmed superficial lesions where surgery is less suitable. Local inflammation is expected, but incomplete response can leave tumour behind. Follow-up is necessary; see skin care.

When to seek urgent care

Arrange prompt dermatology review for a growing, repeatedly bleeding, ulcerated or non-healing lesion. Eye involvement, uncontrolled bleeding or signs of severe treatment reaction need urgent assessment.